HDPCR Technology-Based Non-Small-Cell Lung Cancer Assay to Expand Options for Faster, Targeted Treatment

By LabMedica International staff writers
Posted on 14 Jul 2023

Image: HDPCR is a fast and simplified approach to genomic profiling focused on actionable biomarkers (Photo courtesy of ChromaCode)

Non-small-cell lung cancer (NSCLC) represents the majority of lung cancer cases. Though targeted therapies have enhanced NSCLC survival rates recently, only around half of the patients receive timely biomarker testing for driver mutations to obtain targeted treatment. The barriers to this include expense, the absence of local testing facilities, a slow turnaround time for results, and the availability of insufficient or substandard tissue samples. Now, the early-access commercial launch of an NSCLC assay based on innovative High Definition PCR (HDPCR) technology could change all that.

ChromaCode, Inc. (Carlsbad, CA, USA) has launched a new HDPCR assay panel that can identify actionable NSCLC variations in nine significant genes using amplitude modulation and multi-spectral encoding. It requires only a small sample input and, thanks to simplified workflow and cloud-based analysis, can generate results in less than four hours. HDPCR technology offers a revolutionary approach, enabling deep multiplexing of actionable biomarkers in a single, rapid, and economical assay for multiple sample types on standard laboratory dPCR platforms. Its applications extend to oncology, organ transplant monitoring, and other genomics areas. ChromaCode Cloud complements HDPCR by offering quality insights and boosting lab performance. Utilizing proprietary signal processing data algorithms, this easy-to-use, cloud-based solution provides an integrated platform for seamless result analysis, secure data management, and streamlined reporting.

"The Early Access launch is a major milestone achievement for ChromaCode showcasing our oncology genomics platform; we are excited to announce the commercial availability of the NSCLC assay panel today" said Mark McDonough, Chief Executive Officer of ChromaCode. "The ChromaCode team is committed to positively impacting both the survival rates and the quality of life of the patients that we are privileged to serve. We endeavor to do this by providing our physician and laboratory partners with high quality, fast, lower cost solutions such as the ChromaCode HDPCR Non Small Cell Lung Cancer Assay to expand options for faster, targeted treatment."

Related Links:
ChromaCode, Inc.